MADD: Multi-Agent Drug Discovery Orchestra

• URL: http://arxiv.org/abs/2511.08217v1
• Date: Wed, 12 Nov 2025 01:47:19 GMT
• Title: MADD: Multi-Agent Drug Discovery Orchestra
• Authors: Gleb V. Solovev, Alina B. Zhidkovskaya, Anastasia Orlova, Nina Gubina, Anastasia Vepreva, Rodion Golovinskii, Ilya Tonkii, Ivan Dubrovsky, Ivan Gurev, Dmitry Gilemkhanov, Denis Chistiakov, Timur A. Aliev, Ivan Poddiakov, Galina Zubkova, Ekaterina V. Skorb, Vladimir Vinogradov, Alexander Boukhanovsky, Nikolay Nikitin, Andrei Dmitrenko, Anna Kalyuzhnaya, Andrey Savchenko,
• Abstract summary: We present MADD, a multi-agent system that builds and executes customized hit identification pipelines from natural language queries.<n>We pioneer the application of AI-first drug design to five biological targets and release the identified hit molecules.
• Score: 27.45459097009959
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/
• Abstract: Hit identification is a central challenge in early drug discovery, traditionally requiring substantial experimental resources. Recent advances in artificial intelligence, particularly large language models (LLMs), have enabled virtual screening methods that reduce costs and improve efficiency. However, the growing complexity of these tools has limited their accessibility to wet-lab researchers. Multi-agent systems offer a promising solution by combining the interpretability of LLMs with the precision of specialized models and tools. In this work, we present MADD, a multi-agent system that builds and executes customized hit identification pipelines from natural language queries. MADD employs four coordinated agents to handle key subtasks in de novo compound generation and screening. We evaluate MADD across seven drug discovery cases and demonstrate its superior performance compared to existing LLM-based solutions. Using MADD, we pioneer the application of AI-first drug design to five biological targets and release the identified hit molecules. Finally, we introduce a new benchmark of query-molecule pairs and docking scores for over three million compounds to contribute to the agentic future of drug design.

Related papers

• SelfAI: Building a Self-Training AI System with LLM Agents [79.10991818561907]
  SelfAI is a general multi-agent platform that combines a User Agent for translating high-level research objectives into standardized experimental configurations.<n>An Experiment Manager orchestrates parallel, fault-tolerant training across heterogeneous hardware while maintaining a structured knowledge base for continuous feedback.<n>Across regression, computer vision, scientific computing, medical imaging, and drug discovery benchmarks, SelfAI consistently achieves strong performance and reduces redundant trials.
  arXiv  Detail & Related papers  (2025-11-29T09:18:39Z)
• Human-Centric Open-Future Task Discovery: Formulation, Benchmark, and Scalable Tree-Based Search [55.96277616578607]
  We formalize the problem of Human-centric Open-future Task Discovery (HOTD), focusing on identifying tasks that reduce human effort across multiple plausible futures.<n>To facilitate this study, we propose an HOTD-Bench, which features over 2K real-world videos, a semi-automated annotation pipeline, and a simulation-based protocol tailored for open-set future evaluation.<n>We also propose the Collaborative Multi-Agent Search Tree (CMAST), which decomposes the complex reasoning through a multi-agent system and structures the reasoning process through a scalable search tree module.
  arXiv  Detail & Related papers  (2025-11-24T09:33:59Z)
• DrugMCTS: a drug repurposing framework combining multi-agent, RAG and Monte Carlo Tree Search [10.123162419093973]
  DrugMCTS is a novel framework that integrates RAG, multi-agent collaboration, and Monte Carlo Tree Search for drug repositioning.<n>It employs five specialized agents tasked with retrieving and analyzing molecular and protein information, thereby enabling structured and iterative reasoning.<n>Our results highlight the importance of structured reasoning, agent-based collaboration, and feedback-driven search mechanisms.
  arXiv  Detail & Related papers  (2025-07-10T04:39:55Z)
• R&D-Agent: An LLM-Agent Framework Towards Autonomous Data Science [70.1638335489284]
  High-level machine learning engineering tasks remain labor-intensive and iterative.<n>We introduce R&D-Agent, a comprehensive, decoupled, and framework that formalizes the machine learning process.<n>R&D-Agent defines the MLE into two phases and six components, turning agent design for MLE into a principled, testable process.
  arXiv  Detail & Related papers  (2025-05-20T06:07:00Z)
• DrugPilot: LLM-based Parameterized Reasoning Agent for Drug Discovery [54.79763887844838]
  Large language models (LLMs) integrated with autonomous agents hold significant potential for advancing scientific discovery through automated reasoning and task execution.<n>We introduce DrugPilot, a LLM-based agent system with a parameterized reasoning architecture designed for end-to-end scientific in drug discovery.<n>DrugPilot significantly outperforms state-of-the-art agents such as ReAct and LoT, achieving task completion rates of 98.0%, 93.5%, and 64.0% for simple, multi-tool, and multi-turn scenarios, respectively.
  arXiv  Detail & Related papers  (2025-05-20T05:18:15Z)
• Collaborative Expert LLMs Guided Multi-Objective Molecular Optimization [51.104444856052204]
  We present MultiMol, a collaborative large language model (LLM) system designed to guide multi-objective molecular optimization.<n>In evaluations across six multi-objective optimization tasks, MultiMol significantly outperforms existing methods, achieving a 82.30% success rate.
  arXiv  Detail & Related papers  (2025-03-05T13:47:55Z)
• DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration [24.65716292347949]
  DrugAgent is a multi-agent framework that automates machine learning (ML) programming for drug discovery tasks.<n>Our results show that DrugAgent consistently outperforms leading baselines.
  arXiv  Detail & Related papers  (2024-11-24T03:06:59Z)
• DrugAgent: Multi-Agent Large Language Model-Based Reasoning for Drug-Target Interaction Prediction [8.98329812378801]
  DrugAgent is a multi-agent system for drug-target interaction prediction.<n>It combines multiple specialized perspectives with transparent reasoning.<n>Our approach provides detailed, human-interpretable reasoning for each prediction.
  arXiv  Detail & Related papers  (2024-08-23T21:24:59Z)
• MMedAgent: Learning to Use Medical Tools with Multi-modal Agent [27.314055140281432]
  This paper introduces the first agent explicitly designed for the medical field, named textbfMulti-modal textbfMedical textbfAgent (MMedAgent) Comprehensive experiments demonstrate that MMedAgent achieves superior performance across a variety of medical tasks compared to state-of-the-art open-source methods and even the closed-source model, GPT-4o.
  arXiv  Detail & Related papers  (2024-07-02T17:58:23Z)
• EHRAgent: Code Empowers Large Language Models for Few-shot Complex Tabular Reasoning on Electronic Health Records [47.5632532642591]
  Large language models (LLMs) have demonstrated exceptional capabilities in planning and tool utilization. We propose EHRAgent, an LLM agent empowered with a code interface, to autonomously generate and execute code for multi-tabular reasoning.
  arXiv  Detail & Related papers  (2024-01-13T18:09:05Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.